Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: working on updating assumption 2 per Sandy's comments
Info
titleInformation for Reviewers

Text in black is part of the template used to create this document and is not under review. Please review the blue text; this text represents the changes made to the template that are specific to this QRS instrument.

Please especially note assumptions 7 through 9, which discuss the concept of "conditional branching," and Example 1, which shows an example of data not done due to conditional branching in the electronic version of the PRO-CTCAE. Conditional branching replaces the concept of logically skipped items as it allows for situations (such as in the electronic version of the PRO-CTCAE) where items can be not done due to conditional branching. In this case NIH provides scoring for those items not done due to conditional branching. Because it is known that the items were not done due to the symptom not occurring (e.g., when the frequency item response is "Never"), any remaining items for the symptom are provided a standardized score of "None" or "Not at all", with a numeric value of 0.

Page properties
Title

Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Library Version 1.0 (PRO-CTCAE V1.0)

CDISC ReferenceQuestionnaireSupplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials
QRS Short Name
Page properties
QuestionnaireSupplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials
Title

Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Library Version 1.0 (PRO-CTCAE V1.0)

CDISC ReferenceQRS Short Name

PRO-CTCAE V1.0

QRS Permission StatusApproved
TeamPancreatic Cancer Therapeutic Area Team and CDISC Questionnaires, CDISC Questionnaires, Ratings, and Scales (QRS) Subteam
Supplement Version1.0
StatusDRAFT
Date20222023-0312-3008
NotesThis supplement is intended to be used with other CDISC user guides for specific therapeutic/disease areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical Trials.
Known Issue
  • The concept of “conditional branching” in QRS instruments is when the instrument directs the subject to another item of the instrument based on the result of a response compare for a given condition. This concept was reviewed with the CDISC standards teams and it was agreed to use this term instead of “logically skipped item” moving forward for this QRS instrument use case. A new QRS variable named “QSCBRFL” with the description of “Conditionally Branched Item Flag” has been approved for SDTMIG v4.0. This new variable will streamline the data representation of conditionally branched items.


Revision History

DateVersion
20222023-0312-30081.0 Draft
Info

The CDISC PRO-CTCAE V1.0 supplement version Version 1.0 was developed based on the NCI/NIH PRO-CTCAE® website. The website’s PRO-CTCAE Version 1.0 Release Notes release notes indicate the revisions made by NCI/NIH on the PRO-CTCAE 1.0 instrumentmeasurement system. The instrument’s measurement system version is 1.0 based on the website's release notes (specific correction of typographical errors in the different CRF translations). NCI/NIH will notify CDISC of any major changes in the future that would require a change control to the CDISC PRO-CTCAE V1.0 supplement version.

© 2022 2023 Clinical Data Interchange Standards Consortium, Inc. All rights reserved. 

1 Introduction

This document describes the CDISC implementation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Item Library Version 1.0 (PRO-CTCAE V1.0) instrument.

CDISC did not modify this questionnaires, ratings, and scales (QRS) instrument measurement to meet Clinical Data Acquisition Standards Harmonization (CDASH) case report form (CRF) standards.

The representation of data collected for this instrument measurement is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) Questionnaires (QS) domain model, which can be found at the CDISC website at: https://www.cdisc.org/standards/foundational/sdtmig.

These specific implementation details for this instrument measurement are meant to be used in conjunction with the SDTMIG. All instrument documentation All QRS documentation can be found on the CDISC web site at: https://www.cdisc.org/standards/foundational/qrs.

The CDISC Intellectual Property Policy can be found on the CDISC website at: https://www.cdisc.org/about/bylaws.

1.1 Representations and Warranties, Limitations of Liability, and Disclaimers

This document is a supplement to the SDTMIG for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material.

CDISC specifies how to structure the data that has been collected in a database, not what should be collected or how to conduct clinical assessments or protocols. CDISC disclaims any liability for your use of this material.

Although the United States Food and Drug Administration (US FDA) has provided input with regard to this supplement, this input does not constitute US FDA endorsement of any particular instrument. 

2 Copyright Status

The NATIONAL CANCER INSTITUTE (NCI) at the NATIONAL INSTITUTES OF HEALTH (NIH) owns the copyright for the PRO-CTCAE V1.0 instrument and has made it exempt from copyright restrictionsThe PRO-CTCAE® Measurement System is owned exclusively by National Cancer Institute (NCI). Use of the PRO-CTCAE V1.0 is subject to NCI terms of use policy listed on the website. Based on these terms of use, CDISC considers this instrument exempt from copyright restrictions. CDISC has included this supplement in the CDISC inventory of QRS data standards supplements. Hence, CDISC developed QSTESTCD and QSTEST for each item based on the actual text on the instrument measurement system

The CDISC documentation of this instrument consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values.

Note: CDISC Controlled Terminology is maintained by NCI Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

CDISC has developed this documentation at no cost to copyright holder or any additional cost to users of the instrument beyond the normal licenses fees charged by the copyright holder.

CDISC acknowledges Sandra Mitchell, PhD, CRNP, Research Scientist and Program Director Scientific Lead, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Outcomes Research Branch; Healthcare Delivery Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, for the approval to include the PRO-CTCAE V1.0 in the CDISC data standards.

Reference for the PRO-CTCAE V1.0:

  • These materials discuss and/or include the PRO-CTCAE® Item Library Version 1.0 (PRO-CTCAE V1.0). The PRO-CTCAE® Measurement System is owned exclusively by the National Cancer Institute. No part of the PRO-CTCAE® Measurement System may be adapted, altered, amended, abridged, modified, condensed, made into derivative works, or translated without prior written permission from the US National Cancer Institute. PRO-CTCAE is a registered trademark of the US Department of Health & Human Services. All rights reserved. For additional terms of use and to access PRO-CTCAE® Measurement System content, visit https://healthcaredelivery.cancer.gov/pro-ctcae/.
  • The PRO-CTCAE trademark items and information herein were developed by the Division of Cancer Control and Population Sciences in the National Cancer Institute at the National Institutes of Health, Bethesda, Maryland, USA. Use of the PRO-CTCAE is subject to NCI’s Terms of Use. PRO-CTCAE Measurement System content should be downloaded using the Instruments & Form Builder link (https://healthcaredelivery.cancer.gov/pro-ctcae/).

The CDISC documentation of this measurement system consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values (referred to hereafter as annotated Item Library v1.0 form).

Note: CDISC Controlled Terminology is maintained by NCI Enterprise Vocabulary Services (EVS). The most recent version should be accessed through the CDISC website at: https://www.cdisc.org/standards/terminology/controlled-terminology.

CDISC has developed this documentation at no cost to the owner, trademark holder, or users of the measurement system.

CDISC acknowledges Sandra Mitchell, PhD, CRNP, Research Scientist and Program Director Scientific Lead, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Outcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, for the approval to include the PRO-CTCAE V1.0 in the CDISC data standards.

References for the PRO-CTCAE V1.0:

  • Basch E, Reeve BB, Mitchell
  • These materials discuss and/or include the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Item Library Version 1.0 Version Date 4/26/2020 (PRO-CTCAE V1.0) which is owned exclusively by the Division of Cancer Control and Population Sciences in the NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH (NCI). No part of the PRO-CTCAE V1.0 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying recording, or other electronic or mechanical methods, without the prior written permission of NCI and payment of any applicable fees. PRO-CTCAE V1.0 copyright, NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH (NCI). All rights reserved.
  • The PRO-CTCAE trademark items and information herein were developed by the Division of Cancer Control and Population Sciences in the NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE is subject to NCI's "Terms of Use". PRO-CTCAE Measurement System content should be downloaded using the "Instrument & Form Builder". https://healthcaredelivery.cancer.gov/prot-ctcae/. (Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).J Natl Cancer Inst 2014 Sept Sep 29;106(9)).
  • [1] National Institutes of Health – National Cancer Institute, Division of Cancer Control & Population Sciences. (2017, July 2) https://healthcaredelivery.cancer.gov/pro-ctcae/overview.html

3 The QS Domain Model

3.1 Assumptions for the QS Domain Model

All assumptions and business rules described in the SDTMIG QS domain are applicable to this supplement. Additional assumptions specific to the PRO-CTCAE V1.0 are listed below.

The PRO-CTCAE V1.0measurement system is a patient-reported outcome (PRO) instrument developed to capture symptomatic adverse events of patients in cancer clinical trials. The PRO-CTCAE V1.0 was designed to be used in conjunction with the Common Terminology Criteria for Adverse Events (CTCAE).[1] It consists of an item library rather than a static/fixed question item type of instrument. You should . This item library concept is different than other CDISC public domain and copyrighted specific QRS instruments. Users are directed to use the form builder as described on the PRO-CTCAE website to build CRFs and with instructions provided by NCI to select the items to implement it in your a clinical study. The PRO-CTCAE V1.0 includes multiple-choice questions on the frequency, severity, interference, presence/absence, and /or amount of specific adverse events.

Administration of PRO-CTCAE V1.0 may be conducted via different modes, including screen-based, interactive voice response, and paper. Electronic implementation of the PRO-CTCAE V1.0 instrument is measurement system is recommended by NCI/NIH.

  1. As a CDISC QRS standard, the instrument supplement name is PRO-CTCAE V1.0, as provided in this supplementdocument. As an item library, sponsors sponsors may select items from the overall library as a subset of items with the same CDISC Controlled Terminology as appropriate for the condition being studied. It is the users user's responsibility to identify the subset of items used from the overall PRO-CTCAE V1.0 Quick Guide to the Item Library (Version 1.0). The subsetted PRO-CTCAE V1.0 user's instrument measurement system should be titled "PRO-CTCAE sponsor-specified symptoms..." based on the sponsor's discretion when they identify the specific items being used. This will distinctly describe the subsetted instrument measurement system from the overall PRO-CTCAE V1.0. The form builder does not represent the Quick Guide to the Item Library symptom term when creating forms with selected symptoms. Users need to reference the annotated Item Library v1.0 form to obtain the related symptom term for forms based on selected symptoms. 
  2. For the PRO-CTCAE V1.0, QSORRES is populated represented with the text description while ; the numeric rating is represented in the standardized character and numeric result variables QSSTRESC and QSSTRESN. Please reference see the PRO-CTCAE website FAQs for more details on the numeric responsesThe responses for the PRO-CTCAE V1.0 are as follows:
    1. Depending on the symptomatic adverse event (AE) being measured, items assessing symptom presence/absence are rated as follows:Items rated on a binary response scale and rated from 0-1 (e.g(i.e., 0 = “No” and 1 = “Yes”);
    2. Items rated on multiple (more than two) response scale and rated from 0-1 (e.gassessing symptom frequency are rated from 0-4 (i.e., 0 = “No”“Never”, 1 = “Yes”, and “Not applicable” or "Not Applicable"); orItems rated on multiple (more than two) response scale and = “Rarely”, 2 = “Occasionally”, 3 = “Frequently”, and 4 = “Almost constantly”).
    3. Items assessing symptom severity are rated on a 5-point scale rated from 0-1 4 (e.g., 0 = “No”“None”, 1 = “Mild”, 2 = “Yes”, “Not sexually active”, and “Prefer not to answer”“Moderate”, 3 = “Severe”, and 4 = “Very severe”).
    4. Items assessing symptom amount are rated on a 5-point scale and interference are rated from 0-4 (e.g., 0 = “Not at all”, 1 = “A little bit”, 2 = “Somewhat”, 3 = “Quite a bit”, and 4 = “Very much”).
    5. Items assessing symptom frequency are rated on a 5-point scale and amount are rated from 0-4 (e.g., 0 = “Never”“Not at all”, 1 = “Rarely”“A little bit”, 2 = “Occasionally”“Somewhat”, 3 = “Frequently”“Quite a bit”, and 4 = “Almost constantly”, "Not sexually
      active"= “Very much”).
    6. QSTESTCD = "PT01066A " to "PT01071A" sexual symptoms have specific responses.
      1. QSTESTCD=PT01069A and QSTESTCD=PT01070A assessing sexual symptom presence/absence are rated on multiple (more than 2) response scale and rated from 1-0 (e.g., 1 = “Yes” and 0 = “No”, “Not sexually active”, and “Prefer not to answer”).
      Items assessing
      1. QSTESTCD=PT01066A, PT01068A, and PT01071A assessing sexual symptom severity are rated on a 5-point scale

      and are
      1. rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”

      , “Not applicable”
      1. , "Not sexually


      1. active", and “Prefer not to answer”).

      Items assessing symptom interference are
      1. QSTESTCD = "PT01067A" assessing sexual symptom frequency is rated on a 5-point scale
      and are
      1. rated from 0-4 (e.g., 0 =
      “Not at all”
      1. “Never”, 1 =
      “A little bit”
      1. “Rarely”, 2 =
      “Somewhat”
      1. “Occasionally”, 3 =
      “Quite a bit”
      1. “Frequently”,
      and
      1. 4 =
      “Very much”).
  3. The CRF represents up to 5 "other symptoms" to be recorded. In discussions with NIH, it was agreed to provide up to 10 "other symptoms" to be recorded if they existed. QSTESTCDs (QSTESTCDs "PT01082A" thru "PT0191A") and severity of the symptom at its worst (QSTESTCDs "PT01082B" thru "PT0191B").
  4. Total scoring instructions have not yet been developed. Item-level scores are not combined (i.e., No total score nor symptom-specific scores are calculated.).
  5. The time period of evaluation for the PRO-CTCAE V1.0 is populated in the QSEVLINT field in ISO 8601 format when the evaluation interval can be precisely described as duration. The evaluation interval for the PRO-CTCAE V1.0 is the past 7 days (QSEVLINT = "-P7D". Please reference the PRO-CTCAE website for more details on the evaluation interval.
      1. “Almost constantly”, "Not sexually active", and “Prefer not to answer”).
    1. Selected items include additional response options such as "Not applicable", "Not sexually active", and "Prefer not to answer". Users will need to apply a customized value to each of these (e.g., -99 = "Not applicable", 999 = "Not sexually active", and 9999 = "Prefer not to answer"). For example,
      1. QSTESTCD=PT01036A assessing symptom severity is rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”. The response "Not applicable" is also given and could be provided a value of -99.)
  6. The CRF represents up to 5 "other symptoms" to be recorded. In discussions with NIH, it was agreed to provide up to 10 "other symptoms" to be recorded if they existed. QSTESTCDs (QSTESTCDs "PT01082A" through "PT01091A") and severity of the symptom at its worst (QSTESTCDs "PT01082B" through "PT01091B").
  7. PRO-CTCAE V1.0 total scoring instructions have not yet been developed. Item-level scores are not combined (i.e., no total score nor symptom-specific scores are calculated).
  8. The time period of evaluation for the PRO-CTCAE V1.0 is populated in the QSEVLINT field in ISO 8601 format when the evaluation interval can be precisely described as duration. The evaluation interval for the PRO-CTCAE V1.0 is the past 7 days (QSEVLINT = "-P7D"). Please see the PRO-CTCAE website for more details on the evaluation interval.
  9. Items are divided into 15 subcategories represented in the QSSCAT variable. These categorizations represent how the symptom terms are categorized in the PRO-CTCAE V1.0 Item Library (Version 1.0). See Section 4, SDTM Mapping StrategyItems are divided into 14 subcategories represented in the QSSCAT variable. These categorizations represent how the symptom terms are categorized in the PRO-CTCAE V1.0 Item Library (Version 1.0). See Section 4, SDTM Mapping Strategy, for a list of these subcategory values. 
    1. The symptomatic AE being measured by a given item (e.g., the Symptom Term represented on the CRF corresponding to a given item) is stored in the SUPPQS dataset with the QNAM = "QSSYMPTM". This matches the symptom term identified in the PRO-CTCAE V1.0 Quick guide to the Item Library (Version 1.0).. The exception to this is the solicited verbatim symptom terms QSTESTCD = "PT01081 to PT01091B"with QNAM = "OTHER SYMPTOMS".
  10. Conditional Electronic conditional branching is recommended by NCI/NIH in the conduct of the electronic version of the PRO-CTCAE V1.0 for symptom terms that have two 2 or more items. The logic branches from frequency, then to severity, then to interference. For example, if frequency is > (greater than) never, you next pose the severity question, and if severity>noneseverity > none, you pose the interference question. Please reference  Please see the PRO-CTCAE website for more details on the electronic conditional branching approach. .
    1. When a paper version is administered, conditional branching does not apply.
  11. Some items on the PRO-CTCAE may be not done due to conditional branching per the electronic instrument instructions as described in assumption 7. A record is created with the assigned responses based on In the conduct of the PRO-CTCAE V1.0 it expects responses for each item and there should be no missing responses. Electronic branched severity items are assigned responses of 0 = "None" and electronic branched interference items are assigned 0 = "Not al all".
  12. The language in which the PRO-CTCAE V1.0 was administered (e.g., English, Spanish, Japanese) is collected with the Form Builder application and may be represented as a supplemental qualifier with QNAM = "QSDCLANG". Reference the PRO-CTCAE V1.0 website for a list of available language translations.
  13. Terminology
    1. QSCAT, QSTESTCD, and QSTEST values are included in CDISC Controlled Terminology.

    2. A full list of value sets for the qualifier, and result fields is provided in Section 4, SDTM Mapping Strategy.

3.2 Example for the PRO-CTCAE V1.0 QS Domain Model

  1. website FAQ and a QS supplemental qualifier variable is used to indicate an item was conditionally branched. Per NIH, these items are assigned values as follows: severity items are assigned responses of "None" and 0; interference items are assigned "Not at all" and 0. When an item is not done due to conditional branching, it is represented as follows:
    1. QNAM = “QSCBRFL”, QLABEL = “Conditionally Branched Item Flag “, QVAL = “Y” (this is a QS supplemental qualifier variable) 

    2. QSORRES

      1. For severity items, QSORRES = "None"

      2. For interference items, QSORRES = "Not at all"
    3. QSSTRESC = 0 and QSSTRESN = 0
  2. Records are created in qs.xpt for every item on the sponsor's version of the instrument. In the conduct of the PRO-CTCAE V1.0 NIH expects responses for each item and there should be no missing responses. 
    1. For items not done due to conditional branching, refer to assumption 8.
    2. In the unexpected situation where the reason is unknown, then QSORRES, QSSTRESC, and QSSTRESN are all missing; QSSTAT = "NOT DONE"; and QSREASND is missing.
  3. The language in which the PRO-CTCAE V1.0 was administered (e.g., English, Spanish, Japanese) is collected with the Form Builder application and may be represented as a supplemental qualifier with QNAM = "QSLANGDC". See the PRO-CTCAE V1.0 website for a list of available language translations.
  4. Terminology
    1. QSCAT, QSTESTCD, and QSTEST values are included in CDISC Controlled Terminology.

    2. A full list of value sets for the qualifier, and result fields is provided in Section 4, SDTM Mapping Strategy.

3.2 Example for the PRO-CTCAE V1.0 QS Domain Model

The PRO-CTCAE V1.0 example below shows the terminology used to implement the measurement system in the QS domain. This example shows the data for 1 subject collected at the baseline visit for a PRO-CTCAE V1.0. The example uses CDISC Controlled Terminology for QSTESTCD, QSTEST, and QSCAT. All original results, matching the CRF item response text, are represented in QSORRES.The PRO-CTCAE V1.0 example below shows the terminology used to implement the instrument in the QS domain. This example shows the data for 1 subject collected at the baseline visit for a PRO-CTCAE V1.0 instrument. The example uses CDISC Controlled Terminology for QSTESTCD, QSTEST, and QSCAT. All original results, matching the CRF item response text, are represented in QSORRES.This result is then represented as a standard numeric score in QSSTRESN and as a standard character representation in QSSTRESC.

Info

We are unable to make the example consistently show blue in the Wiki. All examples are updated for each QRS instrument so we ask that you please review the example below.

...

you please review the example below.

Example 1: PRO-CTCAE V1.0 measuring the full set of symptoms
The table represents the items from the PRO-CTCAE V1.0 measurement system.

Dataset wrap
Nameqs
Rowcaps
Rows 20-21:

Represent the electronic conditional branching on data entry for the symptom hiccups did not occur and then the symptom of hiccups severity was assigned 0 = “None”.

Rows 24-26:Represent the electronic conditional branching on data entry for the symptom abdominal pain frequency did not occur. The symptom of abdominal pain severity is assigned 0 = “None” and abdominal pain interference is assigned 0 = “Not at all” for the standardized result values.
Rows 126-129:Represent two additional symptoms that existed for the subject.
Rows 130-145:Represent the symptoms "Other Symptom 3 and Other Symptom 3 Severity" through "Other Symptom 10 and Other Symptom 10 Severity" that did not exist for the subject. These symptoms are represented as "NOT DONE".
Dataset2
RowSTUDYIDDOMAINUSUBJIDQSSEQQSTESTCDQSTESTQSCATQSSCATQSORRESQSSTRESCQSSTRESNQSSTATQSREASNDQSLOBXFLVISITNUMQSDTCQSEVLINT
1STUDYXQS23-P00011PT01001APT01-Dry Mouth SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
2STUDYXQS23-P00012PT01002APT01-Difficulty Swallowing SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
3STUDYXQS23-P00013PT01003APT01-Mouth/Throat Sores SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
4STUDYXQS23-P00014PT01003BPT01-Mouth/Throat Sores InterferencePRO-CTCAE V1.0ORALA little bit11

Y12015-05-15-P7D
5STUDYXQS23-P00015PT01004APT01-Cracking Corners of Mouth SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
6STUDYXQS23-P00016PT01005APT01-Voice Quality Changes PresencePRO-CTCAE V1.0ORALNo00

Y12015-05-15-P7D
7STUDYXQS23-P00017PT01006APT01-Hoarseness SeverityPRO-CTCAE V1.0ORALMild11

Y12015-05-15-P7D
8STUDYXQS23-P00018PT01007APT01-Taste Changes SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
9STUDYXQS23-P00019PT01008APT01-Decreased Appetite SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
10STUDYXQS23-P000110PT01008BPT01-Decreased Appetite InterferencePRO-CTCAE V1.0GASTROINTESTINALSomewhat22

Y12015-05-15-P7D
11STUDYXQS23-P000111PT01009APT01-Nausea FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
12STUDYXQS23-P000112PT01009BPT01-Nausea SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
13STUDYXQS23-P000113PT01010APT01-Vomiting FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
14STUDYXQS23-P000114PT01010BPT01-Vomiting SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
15STUDYXQS23-P000115PT01011APT01-Heartburn FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
16STUDYXQS23-P000116PT01011BPT01-Heartburn SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
17STUDYXQS23-P000117PT01012APT01-Gas PresencePRO-CTCAE V1.0GASTROINTESTINALNo00

Y12015-05-15-P7D
18STUDYXQS23-P000118PT01013APT01-Bloating FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
19STUDYXQS23-P000119PT01013BPT01-Bloating SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
20STUDYXQS23-P000120PT01014APT01-Hiccups FrequencyPRO-CTCAE V1.0GASTROINTESTINALNever00

Y12015-05-15-P7D
21STUDYXQS23-P000121PT01014BPT01-Hiccups SeverityPRO-CTCAE V1.0GASTROINTESTINALNone00

Y12015-05-15-P7D
22STUDYXQS23-P000122PT01015APT01-Constipation SeverityPRO-CTCAE V1.0GASTROINTESTINALMild11

Y12015-05-15-P7D
23STUDYXQS23-P000123PT01016APT01-Diarrhea FrequencyPRO-CTCAE V1.0GASTROINTESTINALRarely11

Y12015-05-15-P7D
24STUDYXQS23-P000124PT01017APT01-Abdominal Pain FrequencyPRO-CTCAE V1.0GASTROINTESTINALNever00

Y12015-05-15-P7D
25STUDYXQS23-P000125PT01017BPT01-Abdominal Pain SeverityPRO-CTCAE V1.0GASTROINTESTINALNone00

Y12015-05-15-P7D
26STUDYXQS23-P000126PT01017CPT01-Abdominal Pain InterferencePRO-CTCAE V1.0GASTROINTESTINALNot at all00

Y12015-05-15-P7D
27STUDYXQS23-P000127PT01018APT01-Fecal Incontinence FrequencyPRO-CTCAE V1.0GASTROINTESTINALOccasionally22

Y12015-05-15-P7D
28STUDYXQS23-P000128PT01018BPT01-Fecal Incontinence InterferencePRO-CTCAE V1.0GASTROINTESTINALSomewhat22

Y12015-05-15-P7D
29STUDYXQS23-P000129PT01019APT01-Shortness of Breath SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
30STUDYXQS23-P000130PT01019BPT01-Shortness of Breath InterferencePRO-CTCAE V1.0RESPIRATORYSomewhat22

Y12015-05-15-P7D
31STUDYXQS23-P000131PT01020APT01-Cough SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
32STUDYXQS23-P000132PT01020BPT01-Cough InterferencePRO-CTCAE V1.0RESPIRATORYSomewhat22

Y12015-05-15-P7D
33STUDYXQS23-P000133PT01021APT01-Wheezing SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
34STUDYXQS23-P000134PT01022APT01-Swelling FrequencyPRO-CTCAE V1.0CARDIO/CIRCULATORYOccasionally22

Y12015-05-15-P7D
35STUDYXQS23-P000135PT01022BPT01-Swelling SeverityPRO-CTCAE V1.0CARDIO/CIRCULATORYMild11

Y12015-05-15-P7D
36STUDYXQS23-P000136PT01022CPT01-Swelling InterferencePRO-CTCAE V1.0CARDIO/CIRCULATORYSomewhat22

Y12015-05-15-P7D
37STUDYXQS23-P000137PT01023APT01-Heart Palpitations FrequencyPRO-CTCAE V1.0CARDIO/CIRCULATORYOccasionally22

Y12015-05-15-P7D
38STUDYXQS23-P000138PT01023BPT01-Heart Palpitations SeverityPRO-CTCAE V1.0CARDIO/CIRCULATORYMild11

Y12015-05-15-P7D
39STUDYXQS23-P000139PT01024APT01-Rash PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
40STUDYXQS23-P000140PT01025APT01-Skin Dryness SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
41STUDYXQS23-P000141PT01026APT01-Acne SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
42STUDYXQS23-P000142PT01027APT01-Hair Loss AmountPRO-CTCAE V1.0CUTANEOUSQuite a bit33

Y12015-05-15-P7D
43STUDYXQS23-P000143PT01028APT01-Itching SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
44STUDYXQS23-P000144PT01029APT01-Hives PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
45STUDYXQS23-P000145PT01030APT01-Hand-Foot Syndrome SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
46STUDYXQS23-P000146PT01031APT01-Nail Loss PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
47STUDYXQS23-P000147PT01032APT01-Nail Ridging PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
48STUDYXQS23-P000148PT01033APT01-Nail Discoloration PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
49STUDYXQS23-P000149PT01034APT01-Sensitivity to Sunlight PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
50STUDYXQS23-P000150PT01035APT01-Bed/Pressure Sores PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
51STUDYXQS23-P000151PT01036APT01-Radiation Skin Reaction SeverityPRO-CTCAE V1.0CUTANEOUSMild11

Y12015-05-15-P7D
52STUDYXQS23-P000152PT01037APT01-Skin Darkening PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
53STUDYXQS23-P000153PT01038APT01-Stretch Marks PresencePRO-CTCAE V1.0CUTANEOUSNo00

Y12015-05-15-P7D
54STUDYXQS23-P000154PT01039APT01-Numbness & Tingling SeverityPRO-CTCAE V1.0NEUROLOGICALMild11

Y12015-05-15-P7D
55STUDYXQS23-P000155PT01039BPT01-Numbness & Tingling InterferencePRO-CTCAE V1.0NEUROLOGICALSomewhat22

Y12015-05-15-P7D
56STUDYXQS23-P000156PT01040APT01-Dizziness SeverityPRO-CTCAE V1.0NEUROLOGICALMild11

Y12015-05-15-P7D
57STUDYXQS23-P000157PT01040BPT01-Dizziness InterferencePRO-CTCAE V1.0NEUROLOGICALSomewhat22

Y12015-05-15-P7D
58STUDYXQS23-P000158PT01041APT01-Blurred Vision SeverityPRO-CTCAE V1.0VISUAL/PERCEPTUALMild11

Y12015-05-15-P7D
59STUDYXQS23-P000159PT01041BPT01-Blurred Vision InterferencePRO-CTCAE V1.0VISUAL/PERCEPTUALSomewhat22

Y12015-05-15-P7D
60STUDYXQS23-P000160PT01042APT01-Flashing Lights in Eyes PresencePRO-CTCAE V1.0VISUAL/PERCEPTUALNo00

Y12015-05-15-P7D
61STUDYXQS23-P000161PT01043APT01-Visual Floaters PresencePRO-CTCAE V1.0VISUAL/PERCEPTUALNo00

Y12015-05-15-P7D
62STUDYXQS23-P000162PT01044APT01-Watery Eyes SeverityPRO-CTCAE V1.0VISUAL/PERCEPTUALMild11

Y12015-05-15-P7D
63
Dataset wrap
Nameqs
1
Rowcaps
Rows 126-129:Represent two additional symptoms that existed for the subject.
Rows 130-145:Represent the symptoms "Other Symptom 3 and Other Symptom 3 Severity" through "Other Symptom 10 and Other Symptom 10 Severity" that did not exist for the subject.
Dataset2
RowSTUDYIDDOMAINUSUBJIDQSSEQQSTESTCDQSTESTQSCATQSSCATQSORRESQSSTRESCQSSTRESNQSLOBXFLVISITNUMQSDTCQSEVLINT
STUDYXQS23-P0001
1
63
PT01001A
PT01044BPT01-
Dry Mouth Severity
Watery Eyes InterferencePRO-CTCAE V1.0
ORAL
VISUAL/PERCEPTUAL
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
2
64STUDYXQS23-P0001
2
64
PT01002A
PT01045APT01-
Difficulty Swallowing
Ringing in Ears SeverityPRO-CTCAE V1.0
ORAL
VISUAL/PERCEPTUALMild11

Y12015-05-15-P7D
3
65STUDYXQS23-P0001
3
65
PT01003A
PT01046APT01-
Mouth/Throat Sores
Concentration Problems SeverityPRO-CTCAE V1.0
ORAL
ATTENTION/MEMORYMild11

Y12015-05-15-P7D
4
66STUDYXQS23-P0001
4
66
PT01003B
PT01046BPT01-
Mouth/Throat Sores
Concentration Problems InterferencePRO-CTCAE V1.0
ORALA little bit1
ATTENTION/MEMORYSomewhat22
1


Y12015-05-15-P7D
5
67STUDYXQS23-P0001
5
67
PT01004A
PT01047APT01-
Cracking Corners of Mouth
Memory Problems SeverityPRO-CTCAE V1.0
ORAL
ATTENTION/MEMORYMild11

Y12015-05-15-P7D
6
68STUDYXQS23-P0001
6
68
PT01005A
PT01047BPT01-
Voice Quality Changes Presence
Memory Problems InterferencePRO-CTCAE V1.
0ORALNo
0ATTENTION/MEMORYSomewhat22
0


Y12015-05-15-P7D
7
69STUDYXQS23-P0001
7
69
PT01006A
PT01048APT01-
Hoarseness Severity
General Pain FrequencyPRO-CTCAE V1.0
ORAL
PAIN
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
8
70STUDYXQS23-P0001
8
70
PT01007A
PT01048BPT01-
Taste Changes
General Pain SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
PAINMild11

Y12015-05-15-P7D
9
71STUDYXQS23-P0001
9
71
PT01008A
PT01048CPT01-
Decreased Appetite Severity
General Pain InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
10
72STUDYXQS23-P0001
10
72
PT01008B
PT01049APT01-
Decreased Appetite Interference
Headache FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Somewhat
Occasionally22

Y12015-05-15-P7D
11
73STUDYXQS23-P0001
11
73
PT01009A
PT01049BPT01-
Nausea Frequency
Headache SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Occasionally
Mild
2
1
2
1

Y12015-05-15-P7D
12
74STUDYXQS23-P0001
12
74
PT01009B
PT01049CPT01-
Nausea Severity
Headache InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
13
75STUDYXQS23-P0001
13
75
PT01010A
PT01050APT01-
Vomiting
Muscle Pain FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
PAINOccasionally22

Y12015-05-15-P7D
14
76STUDYXQS23-P0001
14
76
PT01010B
PT01050BPT01-
Vomiting
Muscle Pain SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
PAINMild11

Y12015-05-15-P7D
15
77STUDYXQS23-P0001
15
77
PT01011A
PT01050CPT01-
Heartburn Frequency
Muscle Pain InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Occasionally
Somewhat22

Y12015-05-15-P7D
16
78STUDYXQS23-P0001
16
78
PT01011B
PT01051APT01-
Heartburn Severity
Joint Pain FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
17
79STUDYXQS23-P0001
17
79
PT01012A
PT01051BPT01-
Gas Presence
Joint Pain SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
No
Mild
0
1
0
1

Y12015-05-15-P7D
18
80STUDYXQS23-P0001
18
80
PT01013A
PT01051CPT01-
Bloating Frequency
Joint Pain InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
PAIN
Occasionally
Somewhat22

Y12015-05-15-P7D
19
81STUDYXQS23-P0001
19
81
PT01013B
PT01052APT01-
Bloating
Insomnia SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKEMild11

Y12015-05-15-P7D
20
82STUDYXQS23-P0001
20
82
PT01014A
PT01052BPT01-
Hiccups Frequency
Insomnia InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKE
Never
Somewhat
0
2
0
2

Y12015-05-15-P7D
21
83STUDYXQS23-P0001
21
83
PT01014B
PT01053APT01-
Hiccups
Fatigue SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKE
None
Mild
0
1
0
1

Y12015-05-15-P7D
22
84STUDYXQS23-P0001
22
84
PT01015A
PT01053BPT01-
Constipation Severity
Fatigue InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
SLEEP/WAKE
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
23
85STUDYXQS23-P0001
23
85
PT01016A
PT01054APT01-
Diarrhea
Anxious FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Rarely
Occasionally
1
2
1
2

Y12015-05-15-P7D
24
86STUDYXQS23-P0001
24
86
PT01017A
PT01054BPT01-
Abdominal Pain Frequency
Anxious SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Never
Mild
0
1
0
1

Y12015-05-15-P7D
25
87STUDYXQS23-P0001
25
87
PT01017B
PT01054CPT01-
Abdominal Pain Severity
Anxious InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
None
Somewhat
0
2
0
2

Y12015-05-15-P7D
26
88STUDYXQS23-P0001
26
88
PT01017C
PT01055APT01-
Abdominal Pain Interference
Discouraged FrequencyPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Not at all
Occasionally
0
2
0
2

Y12015-05-15-P7D
27
89STUDYXQS23-P0001
27
89
PT01018A
PT01055BPT01-
Fecal Incontinence Frequency
Discouraged SeverityPRO-CTCAE V1.0
GASTROINTESTINAL
MOOD
Occasionally
Mild
2
1
2
1

Y12015-05-15-P7D
28
90STUDYXQS23-P0001
28
90
PT01018B
PT01055CPT01-
Fecal Incontinence
Discouraged InterferencePRO-CTCAE V1.0
GASTROINTESTINAL
MOODSomewhat22

Y12015-05-15-P7D
29
91STUDYXQS23-P0001
29
91
PT01019A
PT01056APT01-
Shortness of Breath Severity
Sad FrequencyPRO-CTCAE V1.0
RESPIRATORY
MOOD
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
30
92STUDYXQS23-P0001
30
92
PT01019B
PT01056BPT01-
Shortness of Breath Interference
Sad SeverityPRO-CTCAE V1.0
RESPIRATORY
MOOD
Somewhat
Mild
2
1
2
1

Y12015-05-15-P7D
31
93STUDYXQS23-P0001
31
93
PT01020A
PT01056CPT01-
Cough Severity
Sad InterferencePRO-CTCAE V1.0
RESPIRATORY
MOOD
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
32
94STUDYXQS23-P0001
32
94
PT01020B
PT01057APT01-
Cough Interference
Irregular Menstrual Period PresencePRO-CTCAE V1.0
RESPIRATORY
GYNECOLOGIC/URINARY
Somewhat
No
2
0
2
0

Y12015-05-15-P7D
33
95STUDYXQS23-P0001
33
95
PT01021A
PT01058APT01-
Wheezing Severity
Missed Menstrual Period PresencePRO-CTCAE V1.0
RESPIRATORY
GYNECOLOGIC/URINARY
Mild
No
1
0
1
0

Y12015-05-15-P7D
34
96STUDYXQS23-P0001
34
96
PT01022A
PT01059APT01-
Swelling Frequency
Vaginal Discharge AmountPRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARY
Occasionally
Somewhat22

Y12015-05-15-P7D
35
97STUDYXQS23-P0001
35
97
PT01022B
PT01060APT01-
Swelling
Vaginal Dryness SeverityPRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARYMild11

Y12015-05-15-P7D
36
98STUDYXQS23-P0001
36
98
PT01022C
PT01061APT01-
Swelling Interference
Painful Urination SeverityPRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARY
Somewhat
Mild
2
1
2
1

Y12015-05-15-P7D
37
99STUDYXQS23-P0001
37
99
PT01023A
PT01062APT01-
Heart Palpitations
Urinary Urgency FrequencyPRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARYOccasionally22

Y12015-05-15-P7D
38
100STUDYXQS23-P0001
38
100
PT01023B
PT01062BPT01-
Heart Palpitations Severity
Urinary Urgency InterferencePRO-CTCAE V1.0
CARDIO
GYNECOLOGIC/
CIRCULATORY
URINARY
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
39
191STUDYXQS23-P0001
39
191
PT01024A
PT01063APT01-
Rash Presence
Urinary Frequency FrequencyPRO-CTCAE V1.0
CUTANEOUS
GYNECOLOGIC/URINARY
No
Occasionally
0
2
0
2

Y12015-05-15-P7D
40
102STUDYXQS23-P0001
40
102
PT01025A
PT01063BPT01-
Skin Dryness Severity
Urinary Frequency InterferencePRO-CTCAE V1.0
CUTANEOUS
GYNECOLOGIC/URINARY
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
41
103STUDYXQS23-P0001
41
103
PT01026A
PT01064APT01-
Acne Severity
Urine Color Change PresencePRO-CTCAE V1.0
CUTANEOUS
GYNECOLOGIC/URINARY
Mild
No
1
0
1
0

Y12015-05-15-P7D
42
104STUDYXQS23-P0001
42
104
PT01027A
PT01065APT01-
Hair Loss Amount
Urinary Incontinence FrequencyPRO-CTCAE V1.0
CUTANEOUSQuite a bit3
GYNECOLOGIC/URINARYOccasionally22
3


Y12015-05-15-P7D
43
105STUDYXQS23-P0001
43
105
PT01028A
PT01065BPT01-
Itching Severity
Urinary Incontinence InterferencePRO-CTCAE V1.0
CUTANEOUS
GYNECOLOGIC/URINARY
Mild
Somewhat
1
2
1
2

Y12015-05-15-P7D
44
106STUDYXQS23-P0001
44
106
PT01029A
PT01066APT01-
Hives Presence
Achieve&Maintain Erection SeverityPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
No
Mild
0
1
0
1

Y12015-05-15-P7D
45
107STUDYXQS23-P0001
45
107
PT01030A
PT01067APT01-
Hand-Foot Syndrome Severity
Ejaculation FrequencyPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
46
108STUDYXQS23-P0001
46
108
PT01031A
PT01068APT01-
Nail Loss Presence
Decreased Libido SeverityPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
No
Mild
0
1
0
1

Y12015-05-15-P7D
47
109STUDYXQS23-P0001
47
109
PT01032A
PT01069APT01-
Nail Ridging
Delayed Orgasm PresencePRO-CTCAE V1.0
CUTANEOUS
SEXUALNo00

Y12015-05-15-P7D
48
110STUDYXQS23-P0001
48
110
PT01033A
PT01070APT01-
Nail Discoloration
Unable to Have Orgasm PresencePRO-CTCAE V1.0
CUTANEOUS
SEXUALNo00

Y12015-05-15-P7D
49
111STUDYXQS23-P0001
49
111
PT01034A
PT01071APT01-
Sensitivity to Sunlight Presence
Pain w/Sexual Intercourse SeverityPRO-CTCAE V1.0
CUTANEOUS
SEXUAL
No
Mild
0
1
0
1

Y12015-05-15-P7D
50
112STUDYXQS23-P0001
50
112
PT01035A
PT01072APT01-
Bed/Pressure Sores Presence
Breast Swelling&Tenderness SeverityPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
No
Mild
0
1
0
1

Y12015-05-15-P7D
51
113STUDYXQS23-P0001
51
113
PT01036A
PT01073APT01-
Radiation Skin Reaction Severity
Bruising PresencePRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
Mild
No
1
0
1
0

Y12015-05-15-P7D
52
114STUDYXQS23-P0001
52
114
PT01037A
PT01074APT01-
Skin Darkening Presence
Chills FrequencyPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
No
Occasionally
0
2
0
2

Y12015-05-15-P7D
53
115STUDYXQS23-P0001
53
115
PT01038A
PT01074BPT01-
Stretch Marks Presence
Chills SeverityPRO-CTCAE V1.0
CUTANEOUS
MISCELLANEOUS
No
Mild
0
1
0
1

Y12015-05-15-P7D
54
116STUDYXQS23-P0001
54
116
PT01039A
PT01075APT01-
Numbness & Tingling Severity
Increased Sweating FrequencyPRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUS
Mild
Occasionally
1
2
1
2

Y12015-05-15-P7D
55
117STUDYXQS23-P0001
55
117
PT01039B
PT01075BPT01-
Numbness & Tingling Interference
Increased Sweating SeverityPRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUS
Somewhat
Mild
2
1
2
1

Y12015-05-15-P7D
56
118STUDYXQS23-P0001
56
118
PT01040A
PT01076APT01-
Dizziness Severity
Decreased Sweating PresencePRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUS
Mild
No
1
0
1
0

Y12015-05-15-P7D
57
118STUDYXQS23-P0001
57
118
PT01040B
PT01077APT01-
Dizziness Interference
Hot Flashes FrequencyPRO-CTCAE V1.0
NEUROLOGICAL
MISCELLANEOUS
Somewhat
Occasionally22

Y12015-05-15-P7D
58
120STUDYXQS23-P0001
58
120
PT01041A
PT01077BPT01-
Blurred Vision
Hot Flashes SeverityPRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUSMild11

Y12015-05-15-P7D
59
121STUDYXQS23-P0001
59
121
PT01041B
PT01078APT01-
Blurred Vision Interference
Nosebleed FrequencyPRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUS
Somewhat
Occasionally22

Y12015-05-15-P7D
60
122STUDYXQS23-P0001
60
122
PT01042A
PT01078BPT01-
Flashing Lights in Eyes Presence
Nosebleed SeverityPRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUS
No
Mild
0
1
0
1

Y12015-05-15-P7D
61
123STUDYXQS23-P0001
61
123
PT01043A
PT01079APT01-
Visual Floaters
Pain&Swelling at Inj Site PresencePRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUSNo00

Y12015-05-15-P7D
62
124STUDYXQS23-P0001
62
124
PT01044A
PT01080APT01-
Watery Eyes
Body Odor SeverityPRO-CTCAE V1.0
VISUAL/PERCEPTUAL
MISCELLANEOUSMild11

Y12015-05-15-P7D
63
125STUDYXQS23-P0001
63
125
PT01044B
PT01081PT01-
Watery Eyes Interference
Any Other Symptoms ReportedPRO-CTCAE V1.0
VISUAL/PERCEPTUALSomewhat2
OTHER SYMPTOMSYes11
2


Y12015-05-15-P7D
64
126STUDYXQS23-P0001
64
126
PT01045A
PT01082APT01-
Ringing in Ears Severity
Other Symptom 1PRO-CTCAE V1.0
VISUAL/PERCEPTUALMild
OTHER SYMPTOMSAnother symptom 1Another symptom 1


Y12015-05-15-P7D
65
127STUDYXQS23-P0001
65
127
PT01046A
PT01082BPT01-
Concentration Problems
Other Symptom 1 SeverityPRO-CTCAE V1.0
ATTENTION/MEMORY
OTHER SYMPTOMSMild11

Y12015-05-15-P7D
66
128STUDYXQS23-P0001
66
128
PT01046B
PT01083APT01-
Concentration Problems Interference
Other Symptom 2PRO-CTCAE V1.0
ATTENTION/MEMORYSomewhat
OTHER SYMPTOMSAnother symptom 2Another symptom 2


Y12015-05-15-P7D
67
129STUDYXQS23-P0001
67
129
PT01047A
PT01083BPT01-
Memory Problems
Other Symptom 2 SeverityPRO-CTCAE V1.0
ATTENTION/MEMORY
OTHER SYMPTOMSMild11

Y12015-05-15-P7D
68
130STUDYXQS23-P0001
68
130
PT01047B
PT01084APT01-
Memory Problems Interference
Other Symptom 3PRO-CTCAE V1.0
ATTENTION/MEMORYSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
69
131STUDYXQS23-P0001
69
131
PT01048A
PT01084BPT01-
General Pain Frequency
Other Symptom 3 SeverityPRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
70
132STUDYXQS23-P0001
70
132
PT01048B
PT01085APT01-
General Pain Severity
Other Symptom 4PRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
71
133STUDYXQS23-P0001
71
133
PT01048C
PT01085BPT01-
General Pain Interference
Other Symptom 4 SeverityPRO-CTCAE V1.0
PAINSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
72
134STUDYXQS23-P0001
72
134
PT01049A
PT01086APT01-
Headache Frequency
Other Symptom 5PRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
73
135STUDYXQS23-P0001
73
135
PT01049B
PT01086BPT01-
Headache
Other Symptom 5 SeverityPRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
74
136STUDYXQS23-P0001
74
136
PT01049C
PT01087APT01-
Headache Interference
Other Symptom 6PRO-CTCAE V1.
0PAINSomewhat2
0OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
75
137STUDYXQS23-P0001
75
137
PT01050A
PT01087BPT01-
Muscle Pain Frequency
Other Symptom 6 SeverityPRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
76
138STUDYXQS23-P0001
76
138
PT01050B
PT01088APT01-
Muscle Pain Severity
Other Symptom 7PRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
77
139STUDYXQS23-P0001
77
139
PT01050C
PT01088BPT01-
Muscle Pain Interference
Other Symptom 7 SeverityPRO-CTCAE V1.0
PAINSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
78
140STUDYXQS23-P0001
78
140
PT01051A
PT01089APT01-
Joint Pain Frequency
Other Symptom 8PRO-CTCAE V1.0
PAINOccasionally2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
79
141STUDYXQS23-P0001
79
141
PT01051B
PT01089BPT01-
Joint Pain
Other Symptom 8 SeverityPRO-CTCAE V1.0
PAINMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
80
142STUDYXQS23-P0001
80
142
PT01051C
PT01090APT01-
Joint Pain Interference
Other Symptom 9PRO-CTCAE V1.0
PAINSomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
81
143STUDYXQS23-P0001
81
143
PT01052A
PT01090BPT01-
Insomnia
Other Symptom 9 SeverityPRO-CTCAE V1.0
SLEEP/WAKEMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D
82
144STUDYXQS23-P0001
82
144
PT01052B
PT01091APT01-
Insomnia Interference
Other Symptom 10PRO-CTCAE V1.0
SLEEP/WAKESomewhat2
OTHER SYMPTOMS


NOT DONE
2

Y12015-05-15-P7D
83
145STUDYXQS23-P0001
83
145
PT01053A
PT01091BPT01-
Fatigue
Other Symptom 10 SeverityPRO-CTCAE V1.0
SLEEP/WAKEMild1
OTHER SYMPTOMS


NOT DONE
1

Y12015-05-15-P7D


The SUPPQS dataset shows the items in the QS dataset which have assigned responses (QSCBRFL = "Y") due to electronic conditional branching and also relates the symptom terms from the annotated Item Library v1.0 form to each symptom item represented in the QS dataset.

P7D84STUDYX86
dataset-
wrap
Name
suppqs
QS23-P00018485
Dataset2
tableid
suppqs
STUDYIDRDOMAINUSUBJIDIDVARIDVARVALQNAMQLABELQVALQORIG
PT01053BPT01-Fatigue InterferencePRO-CTCAE V1.0SLEEP/WAKESomewhat22Y12015-05-15-P7D
STUDYXQS23-P0001
85
QSSEQ
PT01054APT01-Anxious FrequencyPRO-CTCAE V1.0MOODOccasionally22Y12015-05-15-P7D
21QSCBRFLConditionally Branched Item FlagYASSIGNED
STUDYXQS23-P0001
86
QSSEQ
PT01054BPT01-Anxious SeverityPRO-CTCAE V1.0MOODMild11Y12015-05-15-P7D87
25QSCBRFLConditionally Branched Item FlagYASSIGNED
STUDYXQS23-P0001QSSEQ26
87PT01054CPT01-Anxious InterferencePRO-CTCAE V1.0MOODSomewhat22Y12015-05-15-P7D88
QSCBRFLConditionally Branched Item FlagYASSIGNED
STUDYXQS23-P0001QSTESTCDPT01001AQSSYMPTMSymptom TermDRY MOUTHCRF
STUDYXQS23-P0001QSTESTCDPT01002A
88
QSSYMPTM
PT01055APT01-Discouraged FrequencyPRO-CTCAE V1.0MOODOccasionally22Y12015-05-15-P7D89
Symptom TermDIFFICULTY SWALLOWINGCRF
STUDYXQS23-P0001QSTESTCDPT01003AQSSYMPTMSymptom TermMOUTH/THROAT SORESCRF
STUDYXQS23-P0001QSTESTCDPT01003B
89
QSSYMPTM
PT01055BPT01-Discouraged SeverityPRO-CTCAE V1.0MOODMild11Y12015-05-15-P7D90
Symptom TermMOUTH/THROAT SORESCRF
STUDYXQS23-P0001QSTESTCDPT01004AQSSYMPTMSymptom TermCRACKING AT THE CORNERS OF THE MOUTH (CHEILOSIS/CHEILITIS)CRF
STUDYXQS23-P0001QSTESTCDPT01005A
90
QSSYMPTM
PT01055CPT01-Discouraged InterferencePRO-CTCAE V1.0MOODSomewhat22Y12015-05-15-P7D91
Symptom TermVOICE QUALITY CHANGESCRF
STUDYXQS23-P0001QSTESTCDPT01006AQSSYMPTMSymptom TermHOARSENESSCRF
STUDYXQS23-P0001QSTESTCDPT01007A
91
QSSYMPTM
PT01056APT01-Sad FrequencyPRO-CTCAE V1.0MOODOccasionally22Y12015-05-15-P7D92
Symptom TermTASTE CHANGESCRF
STUDYXQS23-P0001QSTESTCDPT01008AQSSYMPTMSymptom TermDECREASED APPETITECRF
STUDYXQS23-P0001QSTESTCDPT01008B
92
QSSYMPTM
PT01056BPT01-Sad SeverityPRO-CTCAE V1.0MOODMild11Y12015-05-15-P7D93
Symptom TermDECREASED APPETITECRF
STUDYXQS23-P0001QSTESTCDPT01009AQSSYMPTMSymptom TermNAUSEACRF
STUDYXQS23-P0001QSTESTCDPT01009B
93
QSSYMPTM
PT01056CPT01-Sad InterferencePRO-CTCAE V1.0MOODSomewhat22Y12015-05-15-P7D94
Symptom TermNAUSEACRF
STUDYXQS23-P0001QSTESTCDPT01010AQSSYMPTMSymptom TermVOMITINGCRF
STUDYXQS23-P0001QSTESTCDPT01010B
94
QSSYMPTM
PT01057APT01-Irregular Menstrual Period PresencePRO-CTCAE V1.0GYNECOLOGIC/URINARYNo00Y12015-05-15-P7D95
Symptom TermVOMITINGCRF
STUDYXQS23-P0001QSTESTCDPT01011AQSSYMPTMSymptom TermHEARTBURNCRF
STUDYXQS23-P0001QSTESTCDPT01011B
95
QSSYMPTM
PT01058APT01-Missed Menstrual Period PresencePRO-CTCAE V1.0GYNECOLOGIC/URINARYNo00Y12015-05-15-P7D96
Symptom TermHEARTBURNCRF
STUDYXQS23-P0001QSTESTCDPT01012AQSSYMPTMSymptom TermGASCRF
STUDYXQS23-P0001
96PT01059APT01-Vaginal Discharge AmountPRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat2Y12015-05-15-P7D97
QSTESTCDPT01013AQSSYMPTMSymptom TermBLOATINGCRF
STUDYXQS23-P0001QSTESTCDPT01013BQSSYMPTMSymptom TermBLOATINGCRF
STUDYXQS23-P0001QSTESTCDPT01014A
97
QSSYMPTM
PT01060APT01-Vaginal Dryness SeverityPRO-CTCAE V1.0GYNECOLOGIC/URINARYMild11Y12015-05-15-P7D98
Symptom TermHICCUPSCRF
STUDYXQS23-P0001QSTESTCDPT01014BQSSYMPTMSymptom TermHICCUPSCRF
STUDYXQS23-P0001QSTESTCDPT01015A
98
QSSYMPTM
PT01061APT01-Painful Urination SeverityPRO-CTCAE V1.0GYNECOLOGIC/URINARYMild11Y12015-05-15-P7D99
Symptom TermCONSTIPATIONCRF
STUDYXQS23-P0001QSTESTCDPT01016AQSSYMPTMSymptom TermDIARRHEACRF
STUDYXQS23-P0001QSTESTCD
99
PT01017A
PT01062APT01-Urinary Urgency FrequencyPRO-CTCAE V1.0GYNECOLOGIC/URINARYOccasionally22Y12015-05-15-P7D100
QSSYMPTMSymptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01017BQSSYMPTMSymptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01017C
100
QSSYMPTM
PT01062BPT01-Urinary Urgency InterferencePRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat22Y12015-05-15-P7D191
Symptom TermABDOMINAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01018AQSSYMPTMSymptom TermFECAL INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01018B
191
QSSYMPTM
PT01063APT01-Urinary Frequency FrequencyPRO-CTCAE V1.0GYNECOLOGIC/URINARYOccasionally22Y12015-05-15-P7D102
Symptom TermFECAL INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01019AQSSYMPTMSymptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01019B
102
QSSYMPTM
PT01063BPT01-Urinary Frequency InterferencePRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat22Y12015-05-15-P7D103
Symptom TermSHORTNESS OF BREATHCRF
STUDYXQS23-P0001QSTESTCDPT01020AQSSYMPTMSymptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01020B
103
QSSYMPTM
PT01064APT01-Urine Color Change PresencePRO-CTCAE V1.0GYNECOLOGIC/URINARYNo00Y12015-05-15-P7D104
Symptom TermCOUGHCRF
STUDYXQS23-P0001QSTESTCDPT01021AQSSYMPTMSymptom TermWHEEZINGCRF
STUDYXQS23-P0001QSTESTCDPT01022A
104
QSSYMPTM
PT01065APT01-Urinary Incontinence FrequencyPRO-CTCAE V1.0GYNECOLOGIC/URINARYOccasionally22Y12015-05-15-P7D105
Symptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022BQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022C
105
QSSYMPTM
PT01065BPT01-Urinary Incontinence InterferencePRO-CTCAE V1.0GYNECOLOGIC/URINARYSomewhat22Y12015-05-15-P7D106
Symptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01023AQSSYMPTMSymptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01023B
106
QSSYMPTM
PT01066APT01-Achieve&Maintain Erection SeverityPRO-CTCAE V1.0SEXUALMild11Y12015-05-15-P7D107
Symptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01024AQSSYMPTMSymptom TermRASHCRF
STUDYXQS23-P0001QSTESTCDPT01025A
107
QSSYMPTM
PT01067APT01-Ejaculation FrequencyPRO-CTCAE V1.0SEXUALOccasionally22Y12015-05-15-P7D108
Symptom TermSKIN DRYNESSCRF
STUDYXQS23-P0001QSTESTCDPT01026AQSSYMPTMSymptom TermACNECRF
STUDYXQS23-P0001QSTESTCDPT01027A
108
QSSYMPTM
PT01068APT01-Decreased Libido SeverityPRO-CTCAE V1.0SEXUALMild11Y12015-05-15-P7D109
Symptom TermHAIR LOSSCRF
STUDYXQS23-P0001QSTESTCDPT01028AQSSYMPTMSymptom TermITCHINGCRF
STUDYXQS23-P0001QSTESTCDPT01029A
109
QSSYMPTM
PT01069APT01-Delayed Orgasm PresencePRO-CTCAE V1.0SEXUALNo00Y12015-05-15-P7D110
Symptom TermHIVESCRF
STUDYXQS23-P0001QSTESTCDPT01030AQSSYMPTMSymptom TermHAND-FOOT SYNDROMECRF
STUDYXQS23-P0001QSTESTCDPT01031A
110
QSSYMPTM
PT01070APT01-Unable to Have Orgasm PresencePRO-CTCAE V1.0SEXUALNo00Y12015-05-15-P7D111
Symptom TermNAIL LOSSCRF
STUDYXQS23-P0001QSTESTCDPT01032AQSSYMPTMSymptom TermNAIL RIDGINGCRF
STUDYXQS23-P0001QSTESTCDPT01033A
111
QSSYMPTM
PT01071APT01-Pain w/Sexual Intercourse SeverityPRO-CTCAE V1.0SEXUALMild11Y12015-05-15-P7D112
Symptom TermNAIL DISCOLORATIONCRF
STUDYXQS23-P0001QSTESTCDPT01034AQSSYMPTMSymptom TermSENSITIVITY TO SUNLIGHTCRF
STUDYXQS23-P0001QSTESTCDPT01035A
112
QSSYMPTM
PT01072APT01-Breast Swelling&Tenderness SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D113
Symptom TermBED/PRESSURE SORESCRF
STUDYXQS23-P0001QSTESTCDPT01036AQSSYMPTMSymptom TermRADIATION SKIN REACTIONCRF
STUDYXQS23-P0001QSTESTCDPT01037A
113
QSSYMPTM
PT01073APT01-Bruising PresencePRO-CTCAE V1.0MISCELLANEOUSNo00Y12015-05-15-P7D114
Symptom TermSKIN DARKENINGCRF
STUDYXQS23-P0001QSTESTCDPT01038AQSSYMPTMSymptom TermSTRETCH MARKSCRF
STUDYXQS23-P0001QSTESTCD
114
PT01039A
PT01074APT01-Chills FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D115
QSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01039BQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001QSTESTCDPT01040A
115
QSSYMPTM
PT01074BPT01-Chills SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D116
Symptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01040BQSSYMPTMSymptom TermDIZZINESSCRF
STUDYXQS23-P0001QSTESTCDPT01041A
116
QSSYMPTM
PT01075APT01-Increased Sweating FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D117
Symptom TermBLURRED VISIONCRF
STUDYXQS23-P0001QSTESTCDPT01041BQSSYMPTMSymptom TermBLURRED VISIONCRF
STUDYXQS23-P0001QSTESTCDPT01042A
117
QSSYMPTM
PT01075BPT01-Increased Sweating SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D118
Symptom TermFLASHING LIGHTSCRF
STUDYXQS23-P0001QSTESTCDPT01043AQSSYMPTMSymptom TermVISUAL FLOATERSCRF
STUDYXQS23-P0001QSTESTCDPT01044A
118
QSSYMPTM
PT01076APT01-Decreased Sweating PresencePRO-CTCAE V1.0MISCELLANEOUSNo00Y12015-05-15-P7D
Symptom TermWATERY EYESCRF
STUDYXQS23-P0001QSTESTCDPT01044BQSSYMPTMSymptom TermWATERY EYESCRF
118
STUDYXQS23-P0001
118PT01077APT01-Hot Flashes FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D120
QSTESTCDPT01045AQSSYMPTMSymptom TermRINGING IN EARSCRF
STUDYXQS23-P0001QSTESTCDPT01046A
120
QSSYMPTM
PT01077BPT01-Hot Flashes SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D121
Symptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01046BQSSYMPTMSymptom TermCONCENTRATIONCRF
STUDYXQS23-P0001QSTESTCDPT01047A
121
QSSYMPTM
PT01078APT01-Nosebleed FrequencyPRO-CTCAE V1.0MISCELLANEOUSOccasionally22Y12015-05-15-P7D122
Symptom TermMEMORYCRF
STUDYXQS23-P0001QSTESTCDPT01047BQSSYMPTMSymptom TermMEMORYCRF
STUDYXQS23-P0001QSTESTCD
122
PT01048A
PT01078BPT01-Nosebleed SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D123
QSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01048BQSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01048C
123
QSSYMPTM
PT01079APT01-Pain&Swelling at Inj Site PresencePRO-CTCAE V1.0MISCELLANEOUSNo00Y12015-05-15-P7D124
Symptom TermGENERAL PAINCRF
STUDYXQS23-P0001QSTESTCDPT01049AQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01049B
124
QSSYMPTM
PT01080APT01-Body Odor SeverityPRO-CTCAE V1.0MISCELLANEOUSMild11Y12015-05-15-P7D125
Symptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01049CQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001QSTESTCDPT01050A
125
QSSYMPTM
PT01081PT01-Any Other Symptoms ReportedPRO-CTCAE V1.0OTHER SYMPTOMSYes11Y12015-05-15-P7D126
Symptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCDPT01050BQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCD
126
PT01050C
PT01082A
QSSYMPTM
PT01-Other Symptom 1PRO-CTCAE V1.0OTHER SYMPTOMSAnother symptom 1Another symptom 1Y12015-05-15-P7D127
Symptom TermMUSCLE PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051AQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCD
127
PT01051B
PT01082B
QSSYMPTM
PT01-Other
Symptom
1 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSMild11Y12015-05-15-P7D128
TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCDPT01051CQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001QSTESTCD
128
PT01052A
PT01083A
QSSYMPTM
PT01-Other Symptom 2PRO-CTCAE V1.0OTHER SYMPTOMSAnother symptom 2Another symptom 2Y12015-05-15-P7D129
Symptom TermINSOMNIACRF
STUDYXQS23-P0001QSTESTCDPT01052BQSSYMPTMSymptom TermINSOMNIACRF
STUDYXQS23-P0001QSTESTCD
129
PT01053A
PT01083B
QSSYMPTM
PT01-Other Symptom 2 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSMild11Y12015-05-15-P7D130
Symptom TermFATIGUECRF
STUDYXQS23-P0001QSTESTCDPT01053BQSSYMPTMSymptom TermFATIGUECRF
STUDYXQS23-P0001QSTESTCD
130
PT01054A
PT01084A
QSSYMPTM
PT01-Other Symptom 3PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D131
Symptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCDPT01054BQSSYMPTMSymptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCD
131
PT01054C
PT01084B
QSSYMPTM
PT01-Other Symptom 3 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D132
Symptom TermANXIOUSCRF
STUDYXQS23-P0001QSTESTCDPT01055AQSSYMPTMSymptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCD
132
PT01055B
PT01085A
QSSYMPTM
PT01-Other
Symptom
4PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D133
TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCD
133
PT01055C
PT01085B
QSSYMPTM
PT01-Other Symptom 4 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D134
Symptom TermDISCOURAGEDCRF
STUDYXQS23-P0001QSTESTCDPT01056AQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001QSTESTCD
134
PT01056B
PT01086A
QSSYMPTM
PT01-Other Symptom 5PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D135
Symptom TermSADCRF
STUDYXQS23-P0001QSTESTCDPT01056CQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001QSTESTCD
135
PT01057A
PT01086B
QSSYMPTM
PT01-Other
Symptom
5 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D136
TermIRREGULAR PERIODS/VAGINAL BLEEDINGCRF
STUDYXQS23-P0001QSTESTCD
136
PT01058A
PT01087A
QSSYMPTM
PT01-Other Symptom 6PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D137
Symptom TermMISSED EXPECTED MENSTRUAL PERIODCRF
STUDYXQS23-P0001QSTESTCDPT01059AQSSYMPTMSymptom TermVAGINAL DISCHARGECRF
STUDYXQS23-P0001QSTESTCD
137
PT01060A
PT01087B
QSSYMPTM
PT01-Other
Symptom
6 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D138
TermVAGINAL DRYNESSCRF
STUDYXQS23-P0001QSTESTCD
138
PT01061A
PT01088A
QSSYMPTM
PT01-Other
Symptom
7PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D139
TermPAINFUL URINATIONCRF
STUDYXQS23-P0001QSTESTCD
139
PT01062A
PT01088B
QSSYMPTM
PT01-Other Symptom 7 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D140
Symptom TermURINARY URGENCYCRF
STUDYXQS23-P0001QSTESTCDPT01062BQSSYMPTMSymptom TermURINARY URGENCYCRF
STUDYXQS23-P0001QSTESTCD
140
PT01063A
PT01089A
QSSYMPTM
PT01-Other Symptom 8PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D141
Symptom TermURINARY FREQUENCYCRF
STUDYXQS23-P0001QSTESTCDPT01063BQSSYMPTMSymptom TermURINARY FREQUENCYCRF
STUDYXQS23-P0001QSTESTCD
141
PT01064A
PT01089B
QSSYMPTM
PT01-Other Symptom 8 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D142
Symptom TermCHANGE IN USUAL URINE COLORCRF
STUDYXQS23-P0001QSTESTCD
142
PT01065A
PT01090A
QSSYMPTM
PT01-Other Symptom 9PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D143
Symptom TermURINARY INCONTINENCECRF
STUDYXQS23-P0001QSTESTCDPT01065BQSSYMPTMSymptom TermURINARY INCONTINENCECRF
STUDYXQS23-P0001QSTESTCD
143
PT01066A
PT01090B
QSSYMPTM
PT01-Other Symptom 9 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D144
Symptom TermACHIEVE AND MAINTAIN ERECTIONCRF
STUDYXQS23-P0001QSTESTCDPT01067AQSSYMPTMSymptom TermEJACULATIONCRF
STUDYXQS23-P0001
144PT01091APT01-Other Symptom 10PRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D145
QSTESTCDPT01068AQSSYMPTMSymptom TermDECREASED LIBIDOCRF
STUDYXQS23-P0001QSTESTCD
145
PT01069A
PT01091B
QSSYMPTM
PT01-Other
Symptom
10 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSY12015-05-15-P7D

The suppqs dataset relates the symptom term from the PRO-CTCAE ITEM LIBRARY (Version 1.0) to each symptom item represented in the qs dataset.

CRF
TermDELAYED ORGASMCRF
STUDYXQS23-P0001QSTESTCDPT01070AQSSYMPTMSymptom TermUNABLE TO HAVE ORGASMCRF
STUDYXQS23-P0001QSTESTCDPT01071AQSSYMPTMSymptom TermPAIN W/SEXUAL INTERCOURSECRF
Dataset wrap
Namesuppqs
QORIG
Dataset2
tableidsuppqs.xpt
STUDYIDRDOMAINUSUBJIDIDVARIDVARVALQNAMQLABELQVAL
STUDYXQS23-P0001QSTESTCD
PT01001A
PT01072AQSSYMPTMSymptom Term
DRY MOUTH
BREAST SWELLING AND TENDERNESSCRF
STUDYXQS23-P0001QSTESTCD
PT01002A
PT01073AQSSYMPTMSymptom Term
DIFFICULTY SWALLOWING
BRUISINGCRF
STUDYXQS23-P0001QSTESTCD
PT01003A
PT01074AQSSYMPTMSymptom Term
MOUTH/THROAT SORES
CHILLSCRF
STUDYXQS23-P0001QSTESTCD
PT01003B
PT01074BQSSYMPTMSymptom Term
MOUTH/THROAT SORES
CHILLSCRF
STUDYXQS23-P0001QSTESTCD
PT01004A
PT01075AQSSYMPTMSymptom Term
CRACKING AT THE CORNERS OF THE MOUTH (CHEILOSIS/CHEILITIS)
INCREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCD
PT01005A
PT01075BQSSYMPTMSymptom Term
VOICE QUALITY CHANGES
INCREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCD
PT01006A
PT01076AQSSYMPTMSymptom Term
HOARSENESS
DECREASED SWEATINGCRF
STUDYXQS23-P0001QSTESTCD
PT01007A
PT01077AQSSYMPTMSymptom Term
TASTE CHANGES
HOT FLASHESCRF
STUDYXQS23-P0001QSTESTCD
PT01008A
PT01077BQSSYMPTMSymptom Term
DECREASED APPETITE
HOT FLASHESCRF
STUDYXQS23-P0001QSTESTCD
PT01008B
PT01078AQSSYMPTMSymptom Term
DECREASED APPETITE
NOSEBLEEDCRF
STUDYXQS23-P0001QSTESTCD
PT01009A
PT01078BQSSYMPTMSymptom Term
NAUSEA
NOSEBLEEDCRF
STUDYXQS23-P0001QSTESTCD
PT01009B
PT01079AQSSYMPTMSymptom Term
NAUSEA
PAIN AND SWELLING AT INJECTION SITECRF
STUDYXQS23-P0001QSTESTCD
PT01010A
PT01080AQSSYMPTMSymptom Term
VOMITING
BODY ODORCRF
STUDYXQS23-P0001QSTESTCD
PT01010B
PT01081QSSYMPTMSymptom Term
VOMITING
ANY OTHER SYMPTOMS REPORTEDCRF
STUDYXQS23-P0001QSTESTCD
PT01011A
PT01082AQSSYMPTMSymptom Term
HEARTBURN
OTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCD
PT01011B
PT01082BQSSYMPTMSymptom Term
HEARTBURN
OTHER SYMPTOM 1CRF
STUDYXQS23-P0001QSTESTCD
PT01012A
PT01083AQSSYMPTMSymptom Term
GAS
OTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCD
PT01013A
PT01083BQSSYMPTMSymptom Term
BLOATING
OTHER SYMPTOM 2CRF
STUDYXQS23-P0001QSTESTCD
PT01013B
PT01084AQSSYMPTMSymptom Term
BLOATING
OTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCD
PT01014A
PT01084BQSSYMPTMSymptom Term
HICCUPS
OTHER SYMPTOM 3CRF
STUDYXQS23-P0001QSTESTCD
PT01014B
PT01085AQSSYMPTMSymptom Term
HICCUPS
OTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCD
PT01015A
PT01085BQSSYMPTMSymptom Term
CONSTIPATION
OTHER SYMPTOM 4CRF
STUDYXQS23-P0001QSTESTCD
PT01016A
PT01086AQSSYMPTMSymptom Term
DIARRHEA
OTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCD
PT01017A
PT01086BQSSYMPTMSymptom Term
ABDOMINAL PAIN
OTHER SYMPTOM 5CRF
STUDYXQS23-P0001QSTESTCD
PT01017B
PT01087AQSSYMPTMSymptom Term
ABDOMINAL PAIN
OTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCD
PT01017C
PT01087BQSSYMPTMSymptom Term
ABDOMINAL PAIN
OTHER SYMPTOM 6CRF
STUDYXQS23-P0001QSTESTCD
PT01018A
PT01088AQSSYMPTMSymptom Term
FECAL INCONTINENCE
OTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCD
PT01018B
PT01088BQSSYMPTMSymptom Term
FECAL INCONTINENCE
OTHER SYMPTOM 7CRF
STUDYXQS23-P0001QSTESTCD
PT01019A
PT01089AQSSYMPTMSymptom Term
SHORTNESS OF BREATH
OTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCD
PT01019B
PT01089BQSSYMPTMSymptom Term
SHORTNESS OF BREATH
OTHER SYMPTOM 8CRF
STUDYXQS23-P0001QSTESTCD
PT01020A
PT01090AQSSYMPTMSymptom Term
COUGH
OTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCD
PT01020B
PT01090BQSSYMPTMSymptom Term
COUGH
OTHER SYMPTOM 9CRF
STUDYXQS23-P0001QSTESTCD
PT01021A
PT01091AQSSYMPTMSymptom Term
WHEEZING
OTHER SYMPTOM 10CRF
STUDYXQS23-P0001QSTESTCD
PT01022A
PT01091BQSSYMPTMSymptom Term
SWELLING
OTHER SYMPTOM 10CRF
STUDYXQS23-P0001QSTESTCDPT01022BQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01022CQSSYMPTMSymptom TermSWELLINGCRF
STUDYXQS23-P0001QSTESTCDPT01023AQSSYMPTMSymptom TermHEART PALPITATIONSCRF
STUDYXQS23-P0001QSTESTCDPT01023BQSSYMPTMSymptom TermHEART PALPITATIONS

Example 2: PRO-CTCAE V1.0 measuring the subset of symptoms from the following subcategories as represented in the Quick Guide to the Item Library:

  • RESPIRATORY
  • CARDIO/CIRCULATORY
  • NEUROLOGICAL
  • ATTENTION/MEMORY

The table represents the subset of items from the PRO-CTCAE V1.0 measurement system. The subject did not have any symptoms represented with "Other Symptom 3 and Other Symptom 3 Severity" through "Other Symptom 10 and Other Symptom 10 Severity". These records are represented as "NOT DONE".

Dataset wrap
Nameqsxx
Dataset2
tableidqsxx
RowSTUDYIDDOMAINUSUBJIDQSSEQQSTESTCDQSTESTQSCATQSSCATQSORRESQSSTRESCQSSTRESNQSSTATQSREASNDQSLOBXFLVISITNUMQSDTCQSEVLINT
1STUDYXQS23-P0001
QSTESTCD
1
PT01024AQSSYMPTMSymptom TermRASHCRFSTUDYXQS23-P0001QSTESTCDPT01025AQSSYMPTMSymptom TermSKIN DRYNESS
PT01019APT01-Shortness of Breath SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
2
CRF
STUDYXQS23-P0001
QSTESTCD
2
PT01026AQSSYMPTMSymptom TermACNECRFSTUDYXQS23-P0001QSTESTCDPT01027AQSSYMPTMSymptom TermHAIR LOSS
PT01019BPT01-Shortness of Breath InterferencePRO-CTCAE V1.0RESPIRATORYSomewhat22

Y12015-05-15-P7D
3
CRF
STUDYXQS23-P0001
QSTESTCDPT01028AQSSYMPTMSymptom TermITCHINGCRF
3PT01020APT01-Cough SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
4
STUDYXQS23-P0001QSTESTCDPT01029AQSSYMPTMSymptom TermHIVESCRF
STUDYXQS23-P0001
QSTESTCD
4
PT01030AQSSYMPTMSymptom TermHAND-FOOT SYNDROMECRF
PT01020BPT01-Cough InterferencePRO-CTCAE V1.0RESPIRATORYSomewhat22

Y12015-05-15-P7D
5
STUDYXQS23-P0001QSTESTCDPT01031AQSSYMPTMSymptom TermNAIL LOSSCRF
STUDYXQS23-P0001
QSTESTCD
5
PT01032AQSSYMPTMSymptom TermNAIL RIDGINGCRF
PT01021APT01-Wheezing SeverityPRO-CTCAE V1.0RESPIRATORYMild11

Y12015-05-15-P7D
6
STUDYXQS23-P0001QSTESTCDPT01033AQSSYMPTMSymptom TermNAIL DISCOLORATIONCRF
STUDYXQS23-P0001
QSTESTCDPT01034AQSSYMPTMSymptom TermSENSITIVITY TO SUNLIGHT
6PT01022APT01-Swelling FrequencyPRO-CTCAE V1.0CARDIO/CIRCULATORYOccasionally22

Y12015-05-15-P7D
7
CRF
STUDYXQS23-P0001
QSTESTCD
7
PT01035AQSSYMPTMSymptom TermBED/PRESSURE SORESCRF
PT01022BPT01-Swelling SeverityPRO-CTCAE V1.0CARDIO/CIRCULATORYMild11

Y12015-05-15-P7D
8
STUDYXQS23-P0001QSTESTCDPT01036AQSSYMPTMSymptom TermRADIATION SKIN REACTIONCRF
STUDYXQS23-P0001
QSTESTCD
8
PT01037AQSSYMPTMSymptom TermSKIN DARKENINGCRF
PT01022CPT01-Swelling InterferencePRO-CTCAE V1.0CARDIO/CIRCULATORYSomewhat22

Y12015-05-15-P7D
9
STUDYXQS23-P0001QSTESTCDPT01038AQSSYMPTMSymptom TermSTRETCH MARKSCRF
STUDYXQS23-P0001
QSTESTCD
9
PT01039AQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
PT01023APT01-Heart Palpitations FrequencyPRO-CTCAE V1.0CARDIO/CIRCULATORYOccasionally22

Y12015-05-15-P7D
10
STUDYXQS23-P0001QSTESTCDPT01039BQSSYMPTMSymptom TermNUMBNESS & TINGLINGCRF
STUDYXQS23-P0001
QSTESTCD
10
PT01040AQSSYMPTMSymptom TermDIZZINESSCRF
PT01023BPT01-Heart Palpitations SeverityPRO-CTCAE V1.0CARDIO/CIRCULATORYMild11

Y12015-05-15-P7D
11
STUDYXQS23-P0001QSTESTCDPT01040BQSSYMPTMSymptom TermDIZZINESSCRF
STUDYXQS23-P0001
QSTESTCDPT01041AQSSYMPTMSymptom TermBLURRED VISION
11PT01039APT01-Numbness & Tingling SeverityPRO-CTCAE V1.0NEUROLOGICALMild11

Y12015-05-15-P7D
12
CRF
STUDYXQS23-P0001
QSTESTCD
12
PT01041BQSSYMPTMSymptom TermBLURRED VISIONCRF
PT01039BPT01-Numbness & Tingling InterferencePRO-CTCAE V1.0NEUROLOGICALSomewhat22

Y12015-05-15-P7D
13
STUDYXQS23-P0001QSTESTCDPT01042AQSSYMPTMSymptom TermFLASHING LIGHTSCRF
STUDYXQS23-P0001
QSTESTCD
13
PT01043AQSSYMPTMSymptom TermVISUAL FLOATERSCRF
PT01040APT01-Dizziness SeverityPRO-CTCAE V1.0NEUROLOGICALMild11

Y12015-05-15-P7D
14
STUDYXQS23-P0001QSTESTCDPT01044AQSSYMPTMSymptom TermWATERY EYESCRF
STUDYXQS23-P0001
QSTESTCD
14
PT01044BQSSYMPTMSymptom TermWATERY EYESCRFSTUDYXQS23-P0001QSTESTCDPT01045AQSSYMPTMSymptom TermRINGING IN EARS
PT01040BPT01-Dizziness InterferencePRO-CTCAE V1.0NEUROLOGICALSomewhat22

Y12015-05-15-P7D
15
CRF
STUDYXQS23-P0001
QSTESTCD
15PT01046A
QSSYMPTMSymptom TermCONCENTRATIONCRF
PT01-Concentration Problems SeverityPRO-CTCAE V1.0ATTENTION/MEMORYMild11

Y12015-05-15-P7D
16
STUDYXQS23-P0001QSTESTCDPT01046BQSSYMPTMSymptom TermCONCENTRATIONCRF
STUDYXQS23-P0001
QSTESTCD
16
PT01047AQSSYMPTMSymptom TermMEMORYCRF
PT01046BPT01-Concentration Problems InterferencePRO-CTCAE V1.0ATTENTION/MEMORYSomewhat22

Y12015-05-15-P7D
17
STUDYXQS23-P0001QSTESTCDPT01047BQSSYMPTMSymptom TermMEMORYCRF
STUDYXQS23-P0001
QSTESTCD
17
PT01048AQSSYMPTMSymptom TermGENERAL PAINCRF
PT01047APT01-Memory Problems SeverityPRO-CTCAE V1.0ATTENTION/MEMORYMild11

Y12015-05-15-P7D
18
STUDYXQS23-P0001QSTESTCDPT01048BQSSYMPTMSymptom TermGENERAL PAINCRF
STUDYXQS23-P0001
QSTESTCD
18
PT01048CQSSYMPTMSymptom TermGENERAL PAINCRF
PT01047BPT01-Memory Problems InterferencePRO-CTCAE V1.0ATTENTION/MEMORYSomewhat22

Y12015-05-15-P7D
19
STUDYXQS23-P0001QSTESTCDPT01049AQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001
QSTESTCD
19
PT01049BQSSYMPTMSymptom TermHEADACHECRF
PT01081PT01-Any Other Symptoms ReportedPRO-CTCAE V1.0OTHER SYMPTOMSYes11

Y12015-05-15-P7D
20
STUDYXQS23-P0001QSTESTCDPT01049CQSSYMPTMSymptom TermHEADACHECRF
STUDYXQS23-P0001
QSTESTCD
20
PT01050AQSSYMPTMSymptom TermMUSCLE PAINCRF
PT01082APT01-Other Symptom 1PRO-CTCAE V1.0OTHER SYMPTOMSAnother symptom 1Another symptom 1


Y12015-05-15-P7D
21
STUDYXQS23-P0001QSTESTCDPT01050BQSSYMPTMSymptom TermMUSCLE PAINCRF
STUDYXQS23-P0001
QSTESTCD
21
PT01050CQSSYMPTMSymptom TermMUSCLE PAINCRF
PT01082BPT01-Other Symptom 1 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSMild11

Y12015-05-15-P7D
22
STUDYXQS23-P0001QSTESTCDPT01051AQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001
QSTESTCD
22
PT01051BQSSYMPTMSymptom TermJOINT PAINCRF
PT01083APT01-Other Symptom 2PRO-CTCAE V1.0OTHER SYMPTOMSAnother symptom 2Another symptom 2


Y12015-05-15-P7D
23
STUDYXQS23-P0001QSTESTCDPT01051CQSSYMPTMSymptom TermJOINT PAINCRF
STUDYXQS23-P0001
QSTESTCD
23
PT01052AQSSYMPTMSymptom TermINSOMNIACRF
PT01083BPT01-Other Symptom 2 SeverityPRO-CTCAE V1.0OTHER SYMPTOMSMild11

Y12015-05-15-P7D
24
STUDYXQS23-P0001QSTESTCDPT01052BQSSYMPTMSymptom TermINSOMNIACRF
STUDYXQS23-P0001
QSTESTCDPT01053AQSSYMPTMSymptom TermFATIGUE
24PT01084APT01-Other Symptom 3PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
25
CRF
STUDYXQS23-P0001
QSTESTCDPT01053BQSSYMPTMSymptom TermFATIGUE
25PT01084BPT01-Other Symptom 3 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
26
CRF
STUDYXQS23-P0001
QSTESTCD
26
PT01054AQSSYMPTMSymptom TermANXIOUSCRF
PT01085APT01-Other Symptom 4PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
27
STUDYXQS23-P0001QSTESTCDPT01054BQSSYMPTMSymptom TermANXIOUSCRF
STUDYXQS23-P0001
QSTESTCDPT01054CQSSYMPTMSymptom TermANXIOUS
27PT01085BPT01-Other Symptom 4 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
28
CRF
STUDYXQS23-P0001
QSTESTCD
28
PT01055AQSSYMPTMSymptom TermDISCOURAGEDCRF
PT01086APT01-Other Symptom 5PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
29
STUDYXQS23-P0001QSTESTCDPT01055BQSSYMPTMSymptom TermDISCOURAGEDCRF
STUDYXQS23-P0001
QSTESTCD
29
PT01055CQSSYMPTMSymptom TermDISCOURAGEDCRF
PT01086BPT01-Other Symptom 5 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
30
STUDYXQS23-P0001QSTESTCDPT01056AQSSYMPTMSymptom TermSADCRF
STUDYXQS23-P0001
QSTESTCDPT01056BQSSYMPTMSymptom TermSAD
30PT01087APT01-Other Symptom 6PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
31
CRF
STUDYXQS23-P0001
QSTESTCDPT01056CQSSYMPTMSymptom TermSAD
31PT01087BPT01-Other Symptom 6 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
32
CRF
STUDYXQS23-P0001
QSTESTCD
32
PT01057AQSSYMPTMSymptom TermIRREGULAR PERIODS/VAGINAL BLEEDINGCRF
PT01088APT01-Other Symptom 7PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
33
STUDYXQS23-P0001QSTESTCDPT01058AQSSYMPTMSymptom TermMISSED EXPECTED MENSTRUAL PERIODCRF
STUDYXQS23-P0001
QSTESTCDPT01059AQSSYMPTMSymptom TermVAGINAL DISCHARGE
33PT01088BPT01-Other Symptom 7 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
34
CRF
STUDYXQS23-P0001
QSTESTCDPT01060AQSSYMPTMSymptom TermVAGINAL DRYNESS
34PT01089APT01-Other Symptom 8PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
35
CRF
STUDYXQS23-P0001
QSTESTCD
35
PT01061AQSSYMPTMSymptom TermPAINFUL URINATIONCRF
PT01089BPT01-Other Symptom 8 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
36
STUDYXQS23-P0001QSTESTCDPT01062AQSSYMPTMSymptom TermURINARY URGENCYCRF
STUDYXQS23-P0001
QSTESTCDPT01062BQSSYMPTMSymptom TermURINARY URGENCY
36PT01090APT01-Other Symptom 9PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
37
CRF
STUDYXQS23-P0001
QSTESTCDPT01063AQSSYMPTMSymptom TermURINARY FREQUENCY
37PT01090BPT01-Other Symptom 9 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
38
CRF
STUDYXQS23-P0001
QSTESTCD
38
PT01063BQSSYMPTMSymptom TermURINARY FREQUENCYCRFSTUDYXQS23-P0001QSTESTCDPT01064AQSSYMPTMSymptom TermCHANGE IN USUAL URINE COLOR
PT01091APT01-Other Symptom 10PRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D
39
CRF
STUDYXQS23-P0001
39PT01091BPT01-Other Symptom 10 SeverityPRO-CTCAE V1.0OTHER SYMPTOMS


NOT DONE

12015-05-15-P7D